CompletedPhase 2/3

Glycine vs Placebo for the Schizophrenia Prodrome

United States8 participantsStarted 2006-03

Plain-language summary

Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.

Who can participate

Age range13 Years – 35 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * meet SIPS criteria for schizophrenia prodrome Exclusion Criteria: * history of psychosis

What they're measuring

Scale of Prodromal Symptoms Total Score

Timeframe: Baseline

Change in Scale of Prodromal Symptoms Total Score

Timeframe: Change from Baseline at 8 Weeks

Trial details

NCT IDNCT00291226

SponsorYale University

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2009-07

Results submitted2016-09-06

View on ClinicalTrials.gov More Schizophrenia Prodrome trials